CN106413744B - 用于在出血性疾病治疗中改善止血的人凝血酶原和活化的因子x的组合物 - Google Patents

用于在出血性疾病治疗中改善止血的人凝血酶原和活化的因子x的组合物 Download PDF

Info

Publication number
CN106413744B
CN106413744B CN201580022141.6A CN201580022141A CN106413744B CN 106413744 B CN106413744 B CN 106413744B CN 201580022141 A CN201580022141 A CN 201580022141A CN 106413744 B CN106413744 B CN 106413744B
Authority
CN
China
Prior art keywords
fxa
fii
composition
concentration
hemophilia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580022141.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN106413744A (zh
Inventor
M·多奇卡尔
S·克纳佩
S·蒂尔
P·L·图雷克
F·沙伊夫灵格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Baishen Co
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52727470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106413744(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baishen Co, Baxalta GmbH filed Critical Baishen Co
Publication of CN106413744A publication Critical patent/CN106413744A/zh
Application granted granted Critical
Publication of CN106413744B publication Critical patent/CN106413744B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201580022141.6A 2014-03-14 2015-03-13 用于在出血性疾病治疗中改善止血的人凝血酶原和活化的因子x的组合物 Active CN106413744B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461953496P 2014-03-14 2014-03-14
US61/953,496 2014-03-14
PCT/US2015/020361 WO2015138847A1 (en) 2014-03-14 2015-03-13 Compositions of human prothrombin and activated factor x for improving hemostasis in the treatment of bleeding disorders

Publications (2)

Publication Number Publication Date
CN106413744A CN106413744A (zh) 2017-02-15
CN106413744B true CN106413744B (zh) 2020-09-04

Family

ID=52727470

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580022141.6A Active CN106413744B (zh) 2014-03-14 2015-03-13 用于在出血性疾病治疗中改善止血的人凝血酶原和活化的因子x的组合物

Country Status (9)

Country Link
US (2) US20150258182A1 (OSRAM)
EP (1) EP3116534B1 (OSRAM)
JP (1) JP6535036B2 (OSRAM)
CN (1) CN106413744B (OSRAM)
AU (1) AU2015229222C1 (OSRAM)
ES (1) ES2742898T3 (OSRAM)
NZ (1) NZ724105A (OSRAM)
TW (1) TWI653047B (OSRAM)
WO (1) WO2015138847A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI653047B (zh) 2014-03-14 2019-03-11 百特製藥公司 用於在出血性病症的治療中促進止血的人類凝血酶原及活化因子x的組成物
US11744880B2 (en) 2017-02-09 2023-09-05 Csl Behring Gmbh Blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
EP3590528A1 (en) * 2018-07-06 2020-01-08 Octapharma AG Fx activation process and its use in the preparation of a fxa composition
CN118401262A (zh) 2021-12-30 2024-07-26 巴克斯特国际公司 用于纤维蛋白密封剂的纤维蛋白原和凝血酶溶液以及纤维蛋白密封剂试剂盒

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287180A (en) 1980-01-28 1981-09-01 Baxter Travenol Laboratories, Inc. Method for treating blood clotting factor inhibitors
EP0796623B1 (de) * 1996-03-20 2005-05-25 Baxter Aktiengesellschaft Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen
US9956272B2 (en) 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
EP2547371A1 (en) * 2010-03-15 2013-01-23 Ferrosan Medical Devices A/S A method for promotion of hemostasis and/or wound healing
TWI653047B (zh) 2014-03-14 2019-03-11 百特製藥公司 用於在出血性病症的治療中促進止血的人類凝血酶原及活化因子x的組成物

Also Published As

Publication number Publication date
AU2015229222B2 (en) 2020-08-27
AU2015229222A1 (en) 2016-09-29
US20150258182A1 (en) 2015-09-17
AU2015229222C1 (en) 2020-12-24
CN106413744A (zh) 2017-02-15
US20190231855A1 (en) 2019-08-01
NZ724105A (en) 2023-02-24
JP2017508806A (ja) 2017-03-30
EP3116534B1 (en) 2019-05-29
JP6535036B2 (ja) 2019-06-26
US11160850B2 (en) 2021-11-02
ES2742898T3 (es) 2020-02-17
TWI653047B (zh) 2019-03-11
WO2015138847A1 (en) 2015-09-17
EP3116534A1 (en) 2017-01-18
TW201620545A (zh) 2016-06-16

Similar Documents

Publication Publication Date Title
Levy et al. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding
US11160850B2 (en) Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders
BR112019013858A2 (pt) Regime de fármaco para o tratamento de isquemia cerebral
US20140356377A1 (en) Compounds for use in boosting coagulation
AU2010355558A1 (en) Treatment of coagulopathy with hyperfibrinolysis
KR20160093735A (ko) 혈우병의 예방학적 치료를 위한 인자 ｉｘ를 포함하는 융합 단백질 및 이의 방법
JP3845112B2 (ja) インターロイキン−６を含有する薬剤組成物、及び消耗性凝血出血疾患の治療への該薬剤組成物の使用
Brinkman et al. Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro
Van Laer et al. Compartment syndrome of the forearm with life-threatening bleeding after fasciotomy as the presenting sign of postpartum acquired hemophilia A: a case report
Saito Studies on Fletcher trait and Fitzgerald trait
EP3548092B1 (en) Rmp composition and methods of use
Arun et al. Clotting Factor Concentrates
Sim Protein S in Coagulation and Inflammation
Woods et al. Coagulation factor concentrates for inherited bleeding disorders
HK40014174A (en) Rmp composition and methods of use
HK40014174B (en) Rmp composition and methods of use
Olevsky et al. Diagnosis and Management of Von Willebrand Disease
Rodeghiero et al. Von Willebrand Disease: Clinical Aspects and Practical Management
Cohen Mechanisms of Coagulation Abnormalities and Trauma
Sharathkumar et al. Congenital Bleeding Disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Zug City

Applicant after: Hundred deep limited liability company

Applicant after: Hundred deep company

Address before: Aupu, Switzerland

Applicant before: Hundred deep limited liability company

Applicant before: Hundred deep company

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Aupu, Switzerland

Applicant after: BAXALTA GmbH

Applicant after: BAXALTA Inc.

Address before: Zug City

Applicant before: BAXALTA GmbH

Applicant before: BAXALTA Inc.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20210630

Address after: Osaka

Patentee after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Aupu, Switzerland

Patentee before: BAXALTA GmbH

Patentee before: Baishen Co.

TR01 Transfer of patent right